Want to see NBP full AI Analyst Report?
NBP Stock Chart & Stats
$1.60
-$0.04(-2.44%)
At close: 4:00 PM EDT
$1.60
-$0.04(-2.44%)
Day’s Range― - ―
52-Week Range$1.46 - $6.79
Previous Close$1.69
Volume169.20K
Average Volume (3M)613.91K
Market Cap
$184.61M
Enterprise Value$251.44
Total Cash (Recent Filing)$30.14M
Total Debt (Recent Filing)$438.46K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Sep 01, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding115,381,690
10 Day Avg. Volume302,898
30 Day Avg. Volume613,909
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside462.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetConsistently low debt-to-equity reduces solvency risk and preserves financial flexibility during extended R&D and clinical timelines. This durable balance-sheet strength increases the company's ability to fund trials, negotiate partnerships, and avoid distress-driven dilution over the next several quarters.
FDA Fast Track For Lead AssetFast Track designation for givastomig creates structural regulatory advantage: closer FDA engagement, rolling review eligibility and potential acceleration of a registrational pathway. This meaningfully improves the odds and timing of a market entry if Phase 3 success follows, altering long-term commercial prospects.
Experienced New CEO And Governance ConsolidationAppointment of an experienced biotech leader with regulatory and commercial background strengthens execution capability for late‑stage programs. Durable impact: improved strategic prioritization, partnership sourcing and capital markets navigation, all critical for advancing registrational trials and eventual commercialization.
Bears Say
Persistent Negative Operating And Free Cash FlowMulti-year negative operating and free cash flow indicate structural cash burn tied to R&D and operations. This persistent deficit forces reliance on external financing or partnerships, raising dilution and execution risk and constraining the firm's ability to sustain multi-stage clinical programs without material funding events.
Revenue Collapsed To Near-zero; Unstable Revenue BaseA near-zero revenue base removes internal funding sources and increases dependence on capital markets and milestones. Lack of recurring revenues weakens financial predictability and limits the firm's ability to absorb clinical setbacks or scale commercial operations without significant external capital or partner revenues.
Material IT Control Weaknesses And Auditor ChangeDisclosed material weaknesses in IT controls and a switch of auditors signal governance and reporting remediation needs. Addressing these structural control gaps can divert management attention, increase audit and compliance costs, and temporarily elevate reporting risk—important durable governance concerns for investors.
NovaBridge Biosciences News
NBP FAQ
What was NovaBridge Biosciences’s price range in the past 12 months?
NovaBridge Biosciences lowest stock price was $1.46 and its highest was $6.79 in the past 12 months.
What is NovaBridge Biosciences’s market cap?
NovaBridge Biosciences’s market cap is $184.61M.
When is NovaBridge Biosciences’s upcoming earnings report date?
NovaBridge Biosciences’s upcoming earnings report date is Sep 01, 2026 which is in 30 days.
How were NovaBridge Biosciences’s earnings last quarter?
Currently, no data Available
Is NovaBridge Biosciences overvalued?
According to Wall Street analysts NovaBridge Biosciences’s price is currently Undervalued.
Does NovaBridge Biosciences pay dividends?
NovaBridge Biosciences does not currently pay dividends.
What is NovaBridge Biosciences’s EPS estimate?
NovaBridge Biosciences’s EPS estimate is -0.12.
How many shares outstanding does NovaBridge Biosciences have?
NovaBridge Biosciences has 115,381,690 shares outstanding.
What happened to NovaBridge Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NovaBridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (462.50% Upside)
$9.00 (462.50% Upside)
Blogger Sentiment
Bullish
NBP Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 350.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 3.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Company Description
NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
NBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(462.50% Upside)
Ownership Overview
0.62% Insiders
0.07% Mutual Funds
0.14% Other Institutional Investors
97.98% Public Companies and
Individual Investors